ACCUSTEM SCIENCES, INC.
Income Statement
| Line Item | Aug 2025 | Jun 2025 | May 2025 | Mar 2025 | Dec 2024 | Nov 2024 | Sep 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $60.2K | — | $28.3K | — | — | $31.4K | — |
| SG&A Expense | — | $341.2K | — | $412.1K | — | — | $296.8K | — |
| Operating Income | — | $-401.4K | — | $-440.4K | — | — | $-328.2K | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-401.4K | — | $-440.4K | — | — | $-328.2K | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-401.4K | — | $-440.4K | — | — | $-328.2K | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.02 | — | $-0.03 | — | — | $-0.03 | — |
| EPS (Diluted) | — | $-0.02 | — | $-0.03 | — | — | $-0.03 | — |
| Shares Outstanding (Basic) | 16.1M | 16.1M | 16.1M | 12.7M | 12.1M | 11.3M | 11.3M | 11.3M |
| Shares Outstanding (Diluted) | 16.1M | 16.1M | 16.1M | 12.7M | 12.1M | 11.3M | 11.3M | 11.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |